Table 1.
At presentation | 6 months (calcitriol therapy) | 1 yr (calcitriol therapy) | 1.5 yr (paricalcitol therapy) | 2 yr (paricalcitol therapy) | Normal range | |
---|---|---|---|---|---|---|
BMI | 28.32 (+2.94 SD) | 27.80 (+2.77 SD) | 27.78 (+2.70 SD) | 28.21 (+2.71 SD) | kg/m2 | |
TSH | 4.9 | 1.71 | 11.35 | 4.8 | 3.16 | 0.60–4.84 μIU/mL |
FT4 | 1.14 | 1.31 | 1.22 | 1.12 | 0.9–1.9 ng/dL | |
PTH | 37 | 18 | 12 | 23 | 31 | 10–65 pg/mL |
P | 4.3 | 4.5 | 5.6 | 5.5 | 5.6 | 3.5–5.5 mg/dL |
Ca | 9.6 | 10.1 | 10.0 | 10.2 | 9.9 | 8.5–10.5 mg/dL |
1,25(OH)2D3 | 15.7 | 48 | 114 | 110 | 76 | 18–80 pg/mL |
25(OH)D3 | 14 | 42.8 | 52.9 | 55.3 | 47.8 | 30–100 ng/mL |
ALP | 200 | 210 | 202 | 212 | 233 | 199–440 U/L |
24 hr urine Ca | 185 | 229 | 120 | 148 | Female adults (or >50 kg body weight): <200 mg/24 hours | |
Urine Ca/Cr | 0.21 | 0.27 | 0.22 | 0.17 | <0.22% | |
IgE | 120.5 | 271 | <90 U/mL |